{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000411","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.436989+00:00","generated_at":"2026-06-18T08:38:13.378275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mirum reports FY 2022 LIVMARLI net product sales of $75.1M; Q4 sales up 48% QoQ","bullets":["Full year 2022 LIVMARLI net product sales $75.1M (vs $3.1M in 2021); total revenue $77.1M.","Q4 2022 net sales up 48% vs Q3 2022; U.S. business guided for 50% growth in 2023.","Operating expenses $208.3M for 2022 (up from $192.6M in 2021); cash & investments $251.7M.","sNDA submitted for LIVMARLI in PFIC; data milestones in biliary atresia (H2 2023) and volixibat programs.","Capital raises net $121.9M since Jan 2022; net royalty obligations reduced via Satiogen acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000411","json":"https://secwatch.observer/filing/0001157523-23-000411.json","markdown":"https://secwatch.observer/filing/0001157523-23-000411.md","text":"https://secwatch.observer/filing/0001157523-23-000411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/0001157523-23-000411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/a53358541.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:38:13.378275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}